MD3880818T2 - Nucleic acids for inhibiting expression of LPA in a cell - Google Patents

Nucleic acids for inhibiting expression of LPA in a cell

Info

Publication number
MD3880818T2
MD3880818T2 MDE20210897T MDE20210897T MD3880818T2 MD 3880818 T2 MD3880818 T2 MD 3880818T2 MD E20210897 T MDE20210897 T MD E20210897T MD E20210897 T MDE20210897 T MD E20210897T MD 3880818 T2 MD3880818 T2 MD 3880818T2
Authority
MD
Moldova
Prior art keywords
lpa
cell
nucleic acids
inhibiting expression
expression
Prior art date
Application number
MDE20210897T
Other languages
Romanian (ro)
Inventor
David Anthony Rider
Lucas Bethge
Christian Frauendorf
Adrien Weingaertner
Judith Hauptmann
Sibylle Dames
Steffen Schubert
Stephan Tenbaum
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Priority claimed from PCT/EP2019/081158 external-priority patent/WO2020099476A1/en
Publication of MD3880818T2 publication Critical patent/MD3880818T2/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Prezenta invenţie se referă la produse şi compoziţii şi la utilizările acestora. În special, invenţia se referă la produse de acid nucleic care interferează cu expresia genei LPA sau inhibă exprimarea acesteia, de preferinţă pentru utilizare ca tratament, prevenire sau reducere a riscului de a suferi de boli cardiovasculare cum ar fi boala coronariană sau stenoza aortică sau accidentul vascular cerebral sau orice altă tulburare, patologia sau sindromul legat de niveluri crescute de particule de Lp(a).The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with the expression of the LPA gene or inhibit its expression, preferably for use as a treatment, prevention or reduction of the risk of suffering from cardiovascular diseases such as coronary heart disease or aortic stenosis or stroke stroke or any other disorder, pathology or syndrome related to elevated levels of Lp(a) particles.

MDE20210897T 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of LPA in a cell MD3880818T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2018000811 2018-11-13
EP19174466 2019-05-14
PCT/EP2019/081158 WO2020099476A1 (en) 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (1)

Publication Number Publication Date
MD3880818T2 true MD3880818T2 (en) 2023-01-31

Family

ID=85035533

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20210897T MD3880818T2 (en) 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of LPA in a cell

Country Status (1)

Country Link
MD (1) MD3880818T2 (en)

Similar Documents

Publication Publication Date Title
ZA202003371B (en) Nucleic acids for inhibiting expression of lpa in a cell
PH12021550801A1 (en) Nucleic acids for inhibiting expression of lpa in a cell
Liy et al. Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells
PH12020500622A1 (en) 17á-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4219713A3 (en) Products and compositions
WO2015153760A3 (en) Methods and compositions for prevention or treatment of a nervous system disorder
EA201391032A1 (en) NEW HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS
PH12017500977A1 (en) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
MA39374A1 (en) Triterpenoids exhibiting hiv maturation inhibition activity, substituted in the 3rd position by a non-aromatic ring bearing a haloalkyl substituent
PH12017500114A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2019014530A8 (en) Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
BR112019002204A2 (en) reelin compositions for treating neurological problems
MD3880818T2 (en) Nucleic acids for inhibiting expression of LPA in a cell
MA43960B1 (en) C-3 and c-17 modified triterpenoids used as inhibitors of hiv-1
EP3483271A3 (en) Products and compositions
MA39406B1 (en) Prodrug of 1,1 '- (1,6-dioxo-1,6-hexanediyl) bis-d-proline
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
PH12020551060A1 (en) Methods of treating chronic inflammatory diseases
EA202092092A1 (en) PHARMACEUTICAL COMPOSITIONS WITH HIGH MEDICINAL LOADS OF MEDIUM RENAL TRIGLYCERIDES AND RELATED METHODS
WO2017081218A3 (en) Anti-human il-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of il-3, and their use in a method to detect human il-3
FI3503899T3 (en) Product and method for increasing uridine concentration in blood plasma
WO2024092095A9 (en) Systems, methods, and compositions for treating vascular disease
Cakmak et al. The rare complication of Behcet's syndrome: concomitance of coronary slow flow with acute coronary syndrome
TR201914037A2 (en) THE USE OF ALANTOLACTON AS A DRUG CANDIDATE IN MULTIPLE SCLEROSIS DISEASE